Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE-AF
NCT02764619Phase 3Unknown
- Sponsor
- Svendborg Hospital
- Start
- Dec 2013
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of spironolactone in Atrial fibrillation (AFib) (2 arms), sponsored by Svendborg Hospital. Primary endpoints: Change in diffuse myocardial fibrosis at 12 months, Difference in myocardial stiffness at 12 months and 1 more. Status: unknown.
02
Drugs
spironolactone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02764619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02764619.